Horizon Pharma (HZNP) Reports In-Line Q1 EPS; Lifts FY15 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Horizon Pharma plc Announces First Quarter 2015 Financial Results and Increases 2015 Guidance
May 8, 2015 7:00 AM EDTDUBLIN, IRELAND -- (Marketwired) -- 05/08/15 -- Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced its first quarter 2015 financial results today.
Quarterly Financial Highlights
(in millions except for per share amounts and percentage change) Q1 2015 Q1 2014 Change ---------- ---------- --------- Total net sales $ 113.1 $ 51.9 118% Adjusted EBITDA 37.7 12.1 212% Net loss (19.6) (206.3) NM Adjusted non-GAAP net income 27.9 11.0 154% Net loss per share - basic $ (0.16) $ (3.07) NM Adjusted non-GAAP net income per share - basic 0.22 0.16 38% Net loss per share -... More
Horizon Pharma plc Names Brian K. Beeler Executive Vice President and General Counsel
May 8, 2015 6:30 AM EDTDUBLIN, IRELAND -- (Marketwired) -- 05/08/15 -- Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today named Brian K. Beeler as general counsel, reporting directly to Timothy P. Walbert, chairman, president and chief executive officer, effective immediately. Beeler has also joined the Company's Executive Committee.
"Since Brian joined Horizon Pharma, he has been instrumental in guiding our legal and compliance functions, which are vital to our long-term success," said Timothy P. Walbert, chairman, president and... More
